Supplementary Figure S5 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Supplementary Figure S5. Overall survival in patients with or without baseline liver metastases.
Supplementary Figure S5 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer | Synapse